Phase III trial of hPAM4-Cide (90Y-labelled clivatuzumab tetraxetan) in pancreatic cancer terminated early due to low efficacy- Immunomedics
Immunomedics has announced that the Company is terminating the Phase III PANCRIT-1 trial with hPAM4-Cide (yttrium-90-labeled (90Y) clivatuzumab tetraxetan) in patients with metastatic pancreatic cancer who had received at least two prior therapies, one of which must have been a gemcitabine-containing regimen. The decision to terminate the trial early is based on the recommendation from the independent Data and Safety Monitoring Board (DSMB), following a planned interim analysis of data on overall survival (OS) after more than 50% of the required 371 deaths had occurred.
The interim analysis showed that the treatment arm of 90Y-clivatuzumab tetraxetan combined with low-dose gemcitabine and best supportive care did not demonstrate a sufficient improvement in OS as compared to placebo plus low-dose gemcitabine and best supportive care.
Comment: Yttrium (90Y) clivatuzumab tetraxetan is a humanized monoclonal antibody designed for the treatment of pancreatic cancer. The antibody itself, clivatuzumab, is conjugated with tetraxetan, a chelator for yttrium-90, a radioisotope which destroys the tumour cells.
Related news and insights
NRx Pharmaceuticals announced the publication of peer-reviewed results from a prospective, open-label, administratively controlled trial of aviptadil for the treatment of respiratory failure in patients with Critical COVID-19.
Biogen Inc. announced topline results from its pivotal Phase III VALOR study of tofersen (BIIB 067), an investigational antisense drug being evaluated for people with superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS).
UCB, announced that the FDA has informed the Company that they were unable to complete review of the Biologics License Application (BLA) for bimekizumab for the treatment of moderate to severe plaque psoriasis by the Prescription Drug User Fee Action (PDUFA) date of October 15, 2021.